DK1294714T3 - Trombinreceptorantagonister - Google Patents
TrombinreceptorantagonisterInfo
- Publication number
- DK1294714T3 DK1294714T3 DK01944492T DK01944492T DK1294714T3 DK 1294714 T3 DK1294714 T3 DK 1294714T3 DK 01944492 T DK01944492 T DK 01944492T DK 01944492 T DK01944492 T DK 01944492T DK 1294714 T3 DK1294714 T3 DK 1294714T3
- Authority
- DK
- Denmark
- Prior art keywords
- thrombin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21172400P | 2000-06-15 | 2000-06-15 | |
PCT/US2001/019025 WO2001096330A2 (en) | 2000-06-15 | 2001-06-13 | Thrombin receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1294714T3 true DK1294714T3 (da) | 2007-12-03 |
Family
ID=22788091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01944492T DK1294714T3 (da) | 2000-06-15 | 2001-06-13 | Trombinreceptorantagonister |
Country Status (31)
Country | Link |
---|---|
US (2) | US6645987B2 (da) |
EP (2) | EP1294714B1 (da) |
JP (2) | JP4642318B2 (da) |
KR (1) | KR100604742B1 (da) |
CN (1) | CN1203070C (da) |
AR (1) | AR028952A1 (da) |
AT (1) | ATE368659T1 (da) |
AU (2) | AU6690001A (da) |
BR (1) | BR0111991A (da) |
CA (1) | CA2410177C (da) |
CY (1) | CY1106947T1 (da) |
CZ (1) | CZ20024098A3 (da) |
DE (1) | DE60129698T2 (da) |
DK (1) | DK1294714T3 (da) |
EC (1) | ECSP024390A (da) |
ES (1) | ES2291323T3 (da) |
HK (1) | HK1051183A1 (da) |
HU (1) | HUP0303081A3 (da) |
IL (2) | IL153308A0 (da) |
MX (1) | MXPA02012447A (da) |
MY (1) | MY130642A (da) |
NO (1) | NO325690B1 (da) |
NZ (1) | NZ523075A (da) |
PE (1) | PE20020235A1 (da) |
PL (1) | PL359822A1 (da) |
PT (1) | PT1294714E (da) |
RU (1) | RU2293735C2 (da) |
SK (1) | SK287026B6 (da) |
TW (1) | TWI302913B (da) |
WO (1) | WO2001096330A2 (da) |
ZA (1) | ZA200210099B (da) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
US6645987B2 (en) * | 2000-06-15 | 2003-11-11 | Schering Corporation | Nor-seco himbacine derivatives useful as thrombin receptor antagonists |
US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
PL371948A1 (en) | 2001-10-18 | 2005-07-11 | Schering Corporation | Himbacine analogues as thrombin receptor antagonists |
TW200407110A (en) * | 2001-11-23 | 2004-05-16 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
EP2062890B1 (en) | 2002-04-16 | 2011-01-05 | Schering Corporation | Tricyclic thrombin receptor antagonist |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004078261A1 (en) * | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
ATE536889T1 (de) * | 2003-07-08 | 2011-12-15 | Accumetrics Inc | Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten |
CN1902177A (zh) | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | 新哌啶衍生物 |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US7407753B2 (en) * | 2004-05-24 | 2008-08-05 | Yissum Research Development Company Of The Hebrewuniversityofjerusalem | Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis |
CN1984905B (zh) * | 2004-05-28 | 2011-06-22 | 先灵公司 | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 |
US20060063930A1 (en) * | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
US8563511B2 (en) * | 2004-10-06 | 2013-10-22 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
MX2007004197A (es) | 2004-10-08 | 2007-06-15 | Schering Corp | Antagonistas del receptor de trombina. |
AU2005307861B2 (en) * | 2004-11-18 | 2009-11-12 | Schering Corporation | Methods of using PDE V inhibitors for the treatment of congestive heart failure |
US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
ES2535534T3 (es) * | 2005-01-14 | 2015-05-12 | Merck Sharp & Dohme Corp. | Una síntesis exo-selectiva de los análogos de himbacina |
AR056919A1 (es) * | 2005-01-14 | 2007-11-07 | Schering Corp | SíNTESIS EXO- Y DIASTEREO- SELECTIVAS DE ANÁLOGOS DE HIMBACINA |
EP1863778B1 (en) | 2005-03-31 | 2015-12-30 | Merck Sharp & Dohme Corp. | Spirocyclic thrombin receptor antagonists |
US7595169B2 (en) * | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
US20070219154A1 (en) * | 2005-12-20 | 2007-09-20 | Suxing Liu | Methods for preventing and/or treating a cell proliferative disorder |
AU2006331583A1 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |
US7888369B2 (en) | 2005-12-22 | 2011-02-15 | Schering Corporation | Oxazoloisoquinoline derivatives as thrombin receptor antagonists |
CN101460463A (zh) | 2006-03-29 | 2009-06-17 | 先灵公司 | 可作为凝血酶受体拮抗剂的单环和双环喜巴辛衍生物 |
WO2007120730A2 (en) | 2006-04-13 | 2007-10-25 | Schering Corporation | Fused ring thrombin receptor antagonists |
KR20090031544A (ko) | 2006-06-29 | 2009-03-26 | 쉐링 코포레이션 | 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제 |
AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
WO2008005268A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
EP2037909A2 (en) * | 2006-06-30 | 2009-03-25 | Schering Corporation | Solid dose formulations of a thrombin receptor antagonist |
TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
JPWO2008038692A1 (ja) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | ジアリールケチミン誘導体 |
JP2010505842A (ja) * | 2006-10-04 | 2010-02-25 | シェーリング コーポレイション | トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体 |
AU2007320029A1 (en) * | 2006-10-04 | 2008-05-22 | Schering Corporation | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
WO2008079260A2 (en) * | 2006-12-22 | 2008-07-03 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
WO2008118320A1 (en) * | 2007-03-23 | 2008-10-02 | Schering Corporation | Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
KR20100017576A (ko) * | 2007-05-03 | 2010-02-16 | 아큐메트릭스, 인크. | 트롬빈 수용체 길항제에 의한 혈소판 응집 억제의 측정 방법 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
CN102099340A (zh) | 2008-05-19 | 2011-06-15 | 先灵公司 | 作为因子ixa抑制剂的杂环化合物 |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Msd株式会社 | 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
PL2438060T3 (pl) | 2009-06-04 | 2014-03-31 | Merck Sharp & Dohme | Aktywny metabolit antagonisty receptora trombiny |
EP2440191A2 (en) | 2009-06-08 | 2012-04-18 | Schering Corporation | A thrombin receptor antagonist and clopidogrel fixed dose tablet |
AR077695A1 (es) | 2009-08-04 | 2011-09-14 | Schering Corp | Derivados de pirimidina como inhibidores del factor ixa |
CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011128421A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi | Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren |
ES2527535T3 (es) | 2010-04-16 | 2015-01-26 | Sanofi | Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US8987274B2 (en) | 2011-10-28 | 2015-03-24 | Merck Sharp & Dohme Corp | Macrocycles that increase p53 activity and the uses thereof |
EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
EP2822557B1 (en) | 2012-03-06 | 2017-08-23 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
WO2015013083A1 (en) | 2013-07-22 | 2015-01-29 | Merck Sharp & Dohme Corp. | Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin |
WO2015026685A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
US9808473B2 (en) | 2013-08-22 | 2017-11-07 | Merck Sharp & Dohme Corp. | Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists |
US9701669B2 (en) | 2013-08-22 | 2017-07-11 | Merck Sharp & Dohme Corp. | Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
WO2016058144A1 (en) * | 2014-10-15 | 2016-04-21 | Merck Sharp & Dohme Corp. | Preparation and use of cyclic sulfonamide derivatives as par-1 receptor antagonists |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
EP4185587A1 (en) | 2020-07-22 | 2023-05-31 | JANSSEN Pharmaceutica NV | Compounds useful as factor xia inhibitors |
US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
JP2000229961A (ja) * | 1998-12-11 | 2000-08-22 | Sagami Chem Res Center | ヒドロナフト[2,3−c]フラン誘導体およびその製造方法 |
US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
ATE266025T1 (de) * | 1997-11-25 | 2004-05-15 | Schering Corp | Thrombin-rezeptor antagonisten |
DE19801636A1 (de) * | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte bicyclische Lactone |
US6645987B2 (en) * | 2000-06-15 | 2003-11-11 | Schering Corporation | Nor-seco himbacine derivatives useful as thrombin receptor antagonists |
-
2001
- 2001-06-13 US US09/880,222 patent/US6645987B2/en not_active Expired - Lifetime
- 2001-06-13 TW TW090114230A patent/TWI302913B/zh not_active IP Right Cessation
- 2001-06-13 PE PE2001000558A patent/PE20020235A1/es not_active Application Discontinuation
- 2001-06-13 CA CA2410177A patent/CA2410177C/en not_active Expired - Fee Related
- 2001-06-13 MY MYPI20012768 patent/MY130642A/en unknown
- 2001-06-13 DK DK01944492T patent/DK1294714T3/da active
- 2001-06-13 EP EP01944492A patent/EP1294714B1/en not_active Expired - Lifetime
- 2001-06-13 EP EP10185528.6A patent/EP2301930B1/en not_active Expired - Lifetime
- 2001-06-13 PL PL35982201A patent/PL359822A1/xx unknown
- 2001-06-13 AR ARP010102821A patent/AR028952A1/es active IP Right Grant
- 2001-06-13 JP JP2002510472A patent/JP4642318B2/ja not_active Expired - Fee Related
- 2001-06-13 CZ CZ20024098A patent/CZ20024098A3/cs unknown
- 2001-06-13 AT AT01944492T patent/ATE368659T1/de not_active IP Right Cessation
- 2001-06-13 PT PT01944492T patent/PT1294714E/pt unknown
- 2001-06-13 AU AU6690001A patent/AU6690001A/xx active Pending
- 2001-06-13 MX MXPA02012447A patent/MXPA02012447A/es active IP Right Grant
- 2001-06-13 BR BR0111991-5A patent/BR0111991A/pt not_active Application Discontinuation
- 2001-06-13 KR KR1020027016982A patent/KR100604742B1/ko not_active IP Right Cessation
- 2001-06-13 IL IL15330801A patent/IL153308A0/xx unknown
- 2001-06-13 DE DE60129698T patent/DE60129698T2/de not_active Expired - Lifetime
- 2001-06-13 NZ NZ523075A patent/NZ523075A/en unknown
- 2001-06-13 ES ES01944492T patent/ES2291323T3/es not_active Expired - Lifetime
- 2001-06-13 AU AU2001266900A patent/AU2001266900B2/en not_active Ceased
- 2001-06-13 WO PCT/US2001/019025 patent/WO2001096330A2/en active IP Right Grant
- 2001-06-13 RU RU2003101111/04A patent/RU2293735C2/ru not_active IP Right Cessation
- 2001-06-13 CN CNB018111483A patent/CN1203070C/zh not_active Expired - Fee Related
- 2001-06-13 SK SK1755-2002A patent/SK287026B6/sk not_active IP Right Cessation
- 2001-06-13 HU HU0303081A patent/HUP0303081A3/hu unknown
-
2002
- 2002-12-06 IL IL153308A patent/IL153308A/en not_active IP Right Cessation
- 2002-12-12 NO NO20025965A patent/NO325690B1/no not_active IP Right Cessation
- 2002-12-12 ZA ZA200210099A patent/ZA200210099B/en unknown
- 2002-12-13 EC EC2002004390A patent/ECSP024390A/es unknown
-
2003
- 2003-04-11 HK HK03102658A patent/HK1051183A1/xx not_active IP Right Cessation
- 2003-06-09 US US10/457,256 patent/US6894065B2/en not_active Expired - Lifetime
-
2006
- 2006-12-06 JP JP2006329955A patent/JP2007056043A/ja not_active Withdrawn
-
2007
- 2007-10-22 CY CY20071101356T patent/CY1106947T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1294714T3 (da) | Trombinreceptorantagonister | |
DE60112603D1 (de) | Perkutane aortenklappe | |
DE60140253D1 (de) | Oreinheit | |
DE60110402D1 (de) | Strukturverbaupanele | |
ATE290000T1 (de) | Muscarinagonisten | |
ATE252099T1 (de) | Biarylcarboxamide | |
DE60131369D1 (de) | Luminizenzglucosemessung | |
IS6687A (is) | Pýrasólafleiður | |
NO20023154D0 (no) | Vevspoding | |
NO20031234L (no) | Brönnfilter | |
NO20030447L (no) | Brönnkontroll | |
DE60126562D1 (de) | Durchfflussregelventil | |
ATA2932001A (de) | Schneefräse | |
DE60135663D1 (de) | Ngskopplung | |
DE60119505D1 (de) | Kraftstoffschlauch | |
ATE262530T1 (de) | Indolochinazolinone | |
DE50115290D1 (de) | Wasserklosett | |
ATE298751T1 (de) | 7-oxopyridoryrimidine | |
NO20016231D0 (no) | Luftspaltningsinnretning | |
DE60025150D1 (de) | Brennkammerverwirbelungsanordnung | |
AR028336A1 (es) | 4-hidroxi-tetrahidropiridonas fenilsubstituidas | |
AR028061A1 (es) | 2-enamino-cetonitrilos fenil-substituidos | |
DE10195992T1 (de) | Oberflächenendbearbeitungsbelag | |
ATE284887T1 (de) | Thienopyrrolidinone | |
NO20013985L (no) | Orto-fenylfenolatkonsentrater |